Old Web
English
Sign In
Acemap
>
authorDetail
>
Kathleen J. Yost
Kathleen J. Yost
National Institutes of Health
Medicine
Oncology
Internal medicine
Gemcitabine
Toxicity
5
Papers
47
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Effect of single agent high-dose methotrexate-related acute kidney injury on length of hospitalization and relative dose intensity in adult patients with central nervous system lymphoma
2017
Journal of Oncology Pharmacy Practice
Jennifer S Steward
Heather Bullard
Timothy J. Orourke
Alan D. Campbell
Brett T. Brinker
Kathleen J. Yost
Amy VanderWoude
William L Scott
Polly E. Kintzel
Show All
Source
Cite
Save
Citations (4)
Reduced time for urinary alkalinization before high-dose methotrexate with preadmission oral bicarbonate:
2012
Journal of Oncology Pharmacy Practice
Polly E. Kintzel
Alan D. Campbell
Kathleen J. Yost
Brett T. Brinker
Nicole V. Arradaza
Daniel Frobish
Alison M. Wehr
Timothy J. O'Rourke
Show All
Source
Cite
Save
Citations (13)
Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study
2006
Investigational New Drugs
James H. Doroshow
Sheryl McCoy
John S. Macdonald
Brian F. Issell
Taral Patel
Patrick W. Cobb
Kathleen J. Yost
James L. Abbruzzese
Show All
Source
Cite
Save
Citations (7)
Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer : A southwest oncology group (SWOG) trial
2006
American Journal of Clinical Oncology
Stephen K. Williamson
Sheryl McCoy
David R. Gandara
Shaker R. Dakhil
Kathleen J. Yost
Jorge C. Paradelo
James N. Atkins
Charles D. Blanke
James L. Abbruzzese
Show All
Source
Cite
Save
Citations (12)
1